Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
Completed · Phase 3
Conditions studied: Advanced/Metastatic Gastroesophageal Adenocarcinoma
In brief
The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer. The primary study hypotheses are that lenvatinib plus pembrolizumab plus chemotherapy is superior to chemotherapy alone for both overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), in participants with programmed cell death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 and in all participants.
Key facts
- Study ID
- NCT04662710
- Run by
- Merck Sharp & Dohme LLC
- People needed
- 895
- Starts
- 2020-12-30
- Expected to finish
- 2026-03-30
- Last updated by the study team
- 2026-04-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Has histologically and/or cytologically confirmed diagnosis of previously untreated, locally advanced unresectable or metastatic gastroesophageal adenocarcinoma
- Is not expected to require tumor resection during the treatment course
- Has gastroesophageal adenocarcinoma that is not human epidermal growth factor receptor 2 (HER-2)/neu positive
- Has measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by scan with IV contrast as determined by the local site investigator
- Male participants agree to refrain from donating sperm and agree to either remain abstinent from heterosexual intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for ≥7 days after last dose of lenvatinib or 90 days after last dose of chemotherapy-whichever comes last
- Female participants not pregnant or breastfeeding are eligible to participate if not a women of childbearing potential (WOCBP), or if a WOCBP they either use a contraceptive method that is highly effective OR remain abstinent from heterosexual intercourse as their preferred and usual lifestyle, and do not donate eggs (ova, oocytes) to others or freeze/store for their own use, and abstain from breastfeeding during the intervention period through 120 days after last dose of pembrolizumab, 30 days after last dose of lenvatinib, or 180 days after last dose of chemotherapy-whichever occurs last
- Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale within 3 days prior to the first dose of study treatment
- Has adequately controlled blood pressure with or without antihypertensive medications
- Has adequate organ function
You may not qualify if…
- Has had previous therapy for locally advanced unresectable or metastatic gastric/gastroesophageal junction (GEJ) esophageal adenocarcinoma
- Has had major surgery within 28 days prior to first dose of study interventions
- Has had radiotherapy within 14 days of randomization
- Has a known additional malignancy that is progressing or has required active treatment within the past 5 years
- Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has severe hypersensitivity (≥Grade 3) to treatment with an monoclonal antibody (mAb) or known sensitivity or intolerance to any component of lenvatinib, pembrolizumab, study chemotherapy agents and/or to any excipients, murine proteins, or platinum containing products
- Has had an allogeneic tissue/solid organ transplant
- Has perforation risks or significant gastrointestinal (GI) bleeding
- Has GI obstruction, poor oral intake (CAPOX participants), or difficulty in taking oral medication (CAPOX participants)
- Has received prior therapy with an anti-programmed cell death 1 (PD-1), anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
- Has received prior therapy with anti- vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor or anti-VEGF mAb
- Has received a live or live-attenuated vaccine within 30 days before the first dose of study drug
- Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs)
- Has radiographic evidence of encasement or invasion of a major blood vessel, or of intratumoral cavitation
- Has inadequate cardiac function
- Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
- Has poorly controlled diarrhea
- Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment
- Has peripheral neuropathy ≥Grade 2
- Has a known history of human immunodeficiency virus (HIV) or HIV 1/2 antibodies
- Has a known history of hepatitis B (defined as HBsAg reactive) or known active hepatitis C virus (defined as HCV ribonucleic acid (RNA) [qualitative] is detected) infection
- Has weight loss of >20% within the last 3 months
Where it is running
- Georgetown University Medical Center ( Site 0009) — Washington D.C., District of Columbia, United States
- James Graham Brown Cancer Center ( Site 0017) — Louisville, Kentucky, United States
- Johns Hopkins University ( Site 0052) — Baltimore, Maryland, United States
- Dana Farber Cancer Center ( Site 0019) — Boston, Massachusetts, United States
- UMASS Memorial Medical Center ( Site 0020) — Worcester, Massachusetts, United States
- Henry Ford Health System ( Site 0023) — Detroit, Michigan, United States
- Cancer and Hematology Centers of Western Michigan ( Site 0025) — Grand Rapids, Michigan, United States
- Washington University School of Medicine ( Site 0027) — St Louis, Missouri, United States
- Mount Sinai Hospital ( Site 0051) — New York, New York, United States
- Memorial Sloan Kettering Cancer Center ( Site 0032) — New York, New York, United States
- AHN West Penn Hospital-AHN Esophageal and Lung Institute ( Site 0058) — Pittsburgh, Pennsylvania, United States
- IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0202) — Caba, Buenos Aires, Argentina
- Instituto Medico Alexander Fleming ( Site 0208) — Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
- Fundacion Favaloro ( Site 0201) — Buenos Aires, Argentina
- Hospital Aleman ( Site 0210) — Buenos Aires, Argentina
- Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0207) — Buenos Aires, Argentina
- CEMIC ( Site 0209) — Buenos Aires, Argentina
- Hospital Privado de Cordoba ( Site 0204) — Córdoba, Argentina
- Nepean Hospital ( Site 2305) — Kingswood, New South Wales, Australia
- Wollongong Hospital ( Site 2307) — Wollongong, New South Wales, Australia
- Royal Brisbane and Women s Hospital ( Site 2304) — Herston, Queensland, Australia
- Hollywood Private Hospital-Medical Oncology ( Site 2308) — Nedlands, Western Australia, Australia
- CHU UCL Namur Site de Godinne ( Site 1005) — Yvoir, Namur, Belgium
- UZ Gent ( Site 1002) — Ghent, Oost-Vlaanderen, Belgium
- UCLA Hematology/Oncology - Santa Monica ( Site 0003) — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.